Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9
8.5
来源：
Nature
关键字：
CRISPR
发布时间：
2025-10-27 23:41
摘要：
AMPTX-1 is a targeted glue degrader that selectively degrades BRD9 by recruiting the E3 ligase DCAF16. This innovative approach demonstrates significant in vivo efficacy, with sustained degradation of BRD9 observed in xenograft models. The study highlights the potential of AMPTX-1 as a therapeutic candidate for oncology, showcasing a unique mechanism distinct from traditional PROTACs. Its promising pharmacokinetic properties and ability to engage previously undruggable targets position it as a valuable addition to the drug development landscape.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
AMPTX-1 selectively recruits DCAF16 to degrade BRD9, demonstrating a novel therapeutic approach.
In vivo studies show sustained BRD9 degradation, indicating potential for clinical application.
The compound's mechanism involves covalent recruitment of E3 ligase, enhancing its therapeutic profile.
真实性检查
否
AI评分总结
AMPTX-1 is a targeted glue degrader that selectively degrades BRD9 by recruiting the E3 ligase DCAF16. This innovative approach demonstrates significant in vivo efficacy, with sustained degradation of BRD9 observed in xenograft models. The study highlights the potential of AMPTX-1 as a therapeutic candidate for oncology, showcasing a unique mechanism distinct from traditional PROTACs. Its promising pharmacokinetic properties and ability to engage previously undruggable targets position it as a valuable addition to the drug development landscape.